{"id":6133,"date":"2022-09-18T12:21:26","date_gmt":"2022-09-18T07:51:26","guid":{"rendered":"http:\/\/arasto.com\/product\/lamotrigine\/"},"modified":"2023-05-06T12:29:05","modified_gmt":"2023-05-06T08:59:05","slug":"lamotrigine","status":"publish","type":"product","link":"https:\/\/arasto.com\/fa\/product\/lamotrigine\/","title":{"rendered":"Lamotrigine"},"content":{"rendered":"<p dir=\"ltr\"><strong>Description<\/strong><\/p>\n<p dir=\"ltr\">(USP 44)<\/p>\n<ol dir=\"ltr\">\n<li><strong>Drug Substance General Information (ICH 3.2.S.1)<\/strong><\/li>\n<\/ol>\n<p dir=\"ltr\"><strong>1.1. Nomenclature (ICH 3.2.S.1.1)<\/strong><\/p>\n<p dir=\"ltr\">International non-proprietary name:\u00a0 Lamotrigine (Brand Name: Lamictl)<\/p>\n<p dir=\"ltr\">Compendial name:\u00a0 Lamotrigine<\/p>\n<p dir=\"ltr\">Chemical name:\u00a0 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl); 3,5-Diamino-6-(2,3-dichlorophenyl)-<em>as<\/em>-triazine.<\/p>\n<p dir=\"ltr\">Arasto\u2019s code:\u00a0 LAM<\/p>\n<p dir=\"ltr\">CAS Registry Number: [84057-84-1].<\/p>\n<p dir=\"ltr\">\n<ol dir=\"ltr\">\n<li><strong>Drug Substance General Information (ICH 3.2.S.1)<\/strong><\/li>\n<\/ol>\n<p dir=\"ltr\"><strong>1.2. Structure (ICH 3.2.S.1.2)<\/strong><\/p>\n<p dir=\"ltr\"><img loading=\"lazy\" decoding=\"async\" width=\"500\" height=\"397\" class=\"wp-image-6469 aligncenter\" src=\"https:\/\/arasto.com\/wp-content\/uploads\/2022\/09\/word-image-5761-1.png\" srcset=\"https:\/\/arasto.com\/wp-content\/uploads\/2022\/09\/word-image-5761-1.png 500w, https:\/\/arasto.com\/wp-content\/uploads\/2022\/09\/word-image-5761-1-300x238.png 300w\" sizes=\"auto, (max-width: 500px) 100vw, 500px\" \/><\/p>\n<p dir=\"ltr\">Empirical formula: C<sub>9<\/sub>H<sub>7<\/sub>Cl<sub>2<\/sub>N<sub>5<\/sub><\/p>\n<p dir=\"ltr\">Molecular Weight: 256.09 g\/mol<\/p>\n<p dir=\"ltr\">\n<ol dir=\"ltr\">\n<li><strong>Drug Substance General Information (ICH 3.2.S.1)<\/strong><\/li>\n<\/ol>\n<p dir=\"ltr\"><strong>1.3. General Properties (ICH 3.2.S.1.3)<\/strong><\/p>\n<p dir=\"ltr\">Lamotrigine is a white to off-white crystalline substance.\u00a0 It is administered orally for the treatment of partial seizures, primary generalized tonic-clonic seizures, generalized seizures of\u00a0<a href=\"http:\/\/www.rxlist.com\/script\/main\/art.asp?articlekey=4131\">Lennox-Gastaut syndrome<\/a>\u00a0as well\u00a0<a href=\"http:\/\/www.rxlist.com\/script\/main\/art.asp?articlekey=30743\">bipolar I disorder<\/a>\u00a0to delay the time to occurrence of mood episodes (depression,\u00a0<a href=\"http:\/\/www.rxlist.com\/script\/main\/art.asp?articlekey=4271\">mania<\/a>,\u00a0<a href=\"http:\/\/www.rxlist.com\/script\/main\/art.asp?articlekey=30745\">hypomania<\/a>, mixed episodes).\u00a0 Lamotrigine is very slightly soluble in water (0.17 mg\/ml at 25\u00b0C) and slightly soluble in methanol.\u00a0 \u00a0It is soluble in hot DMSO. Lamotrigine has a pK<sub>a\u00a0<\/sub>if 5.7 (<a href=\"http:\/\/www.healthyplace.com\/other-info\/psychiatric-medications\">http:\/\/www.healthyplace.com\/other-info\/psychiatric-medications<\/a>\u00a0\/lamotrigine- lamictal-full-prescribing-information\/) and log P of 1.19 at pH 7.6 (R.H. Levy, R.H. Matts, B.S. Meldrum, E. Perruca,\u00a0<em>Antiepilectic Drugs<\/em>,\u00a0<strong>2002<\/strong>, Lippincott Williams &amp; Wilkins, USA, p 371).\u00a0 Lamotrigine is stable in acid but undergoes degradation under highly basic conditions (see Stability Studies).\u00a0 LD<sub>50<\/sub>\u00a0for Lamotrigine is 250 mg\/kg oral in rat (http:\/\/www.drugbank.ca\/drugs\/DB00555).<\/p>\n<p dir=\"ltr\">The determination of purity and assay of APIs require comparison of the product with their respective Reference Standards (RS) and Related Compounds (RC or known impurities).\u00a0 Accordingly, ICH regulations on the purity and assay of reference standard and related compounds are clearly defined and must be followed by drug substance and drug product manufacturers.<\/p>\n<p dir=\"ltr\">According to ICH Q7, 11.1 there are 3 types of standards.\u00a0 This is summarized in the following chart and discussed in detail below.<\/p>\n<p dir=\"ltr\"><img loading=\"lazy\" decoding=\"async\" width=\"500\" height=\"482\" class=\"wp-image-6471 aligncenter\" src=\"https:\/\/arasto.com\/wp-content\/uploads\/2022\/09\/word-image-5761-2.png\" srcset=\"https:\/\/arasto.com\/wp-content\/uploads\/2022\/09\/word-image-5761-2.png 500w, https:\/\/arasto.com\/wp-content\/uploads\/2022\/09\/word-image-5761-2-300x289.png 300w\" sizes=\"auto, (max-width: 500px) 100vw, 500px\" \/><\/p>\n<p dir=\"ltr\">\n<p dir=\"ltr\">The impurities provided in the following table represent Secondary Reference Standards (SRS) that are prepared in-house by synthesis or by isolation.\u00a0 Each SRS has undergone extensive characterization ( IR, UV, 1HNMR, 13CNMR. Mass Spec) and determination of its purity and assay (HPLC).\u00a0 For specification of the SRS of those products that have a monograph, the SRS is compared with a pharmacopoeia Primary Reference Standard (UV, HPLC retention time).\u00a0 For specification of those products that do not \u00a0have a monograph (known as \u00a0House Primary Standard), we \u00a0compare their UV \u03b5 or \u05d2 \/<sub>max<\/sub>\u00a0, IR major absorptions, 1HNMR d (ppm) , 13 CNMR \u00a0d (ppm) or HPLC retention time with values reported in the chemical literature for these compounds.<\/p>\n<p dir=\"ltr\"><img loading=\"lazy\" decoding=\"async\" width=\"500\" height=\"266\" class=\"wp-image-6473 aligncenter\" src=\"https:\/\/arasto.com\/wp-content\/uploads\/2022\/09\/word-image-5761-3.png\" srcset=\"https:\/\/arasto.com\/wp-content\/uploads\/2022\/09\/word-image-5761-3.png 500w, https:\/\/arasto.com\/wp-content\/uploads\/2022\/09\/word-image-5761-3-300x160.png 300w\" sizes=\"auto, (max-width: 500px) 100vw, 500px\" \/><\/p>\n<p dir=\"ltr\">\n<ol dir=\"ltr\">\n<li><strong>Primary and Secondary Reference Standard (ICH 3.2.S.5)<\/strong><\/li>\n<\/ol>\n<p dir=\"ltr\"><strong>5.1.\u00a0Active Pharmaceutical Ingredient<\/strong><\/p>\n<p dir=\"ltr\">Primary Reference Standard for lamotrigine is available from United States Pharmacopoeia. We will use a Secondary Reference Standard (previously referred to as Working Standard) for direct control of all batches of lamotrigine.<\/p>\n<p dir=\"ltr\">As per ICH (Q7, 11.1) and ICH (Q6, 2.11, 3.2, 3.3) the Secondary Reference Standards, which include the API and its Related Compounds, must be examined for their proof of structure (characterization), assay and purity and specification (identification by comparison).\u00a0Furthermore, ICH Guideline on the Preparation of Common Technical Document (Q4M), requires that the data obtained from characterization, assay and purity and specification must be included in section 3.2.S.3.2 for Related Compounds (already discussed in that section) and section 3.2.S.5 of the DMF for the API.\u00a0To this end, the Secondary Reference Standards of the API lamotrigine has undergone extensive characterization (UV, IR,\u00a0<sup>1<\/sup>\u00a0H NMR,\u00a0<sup>13<\/sup>C NMR, Mass Spec) to assure its structure, assay and purity (HPLC and\/or titration) and specification (comparison of its HPLC retention time and UV \u05d2 \/<sub>max<\/sub>\u00a0with USP Primary Reference Standard).<\/p>\n<p dir=\"ltr\">The Secondary Reference Standard for lamotrigine was produced from a released batch by subjecting it to an additional crystallization from the final solvent system used in the production of the API to avoid the possibility of other polymorph formation.<\/p>\n<h1 dir=\"ltr\">SPECIFICATION OF ANALYSIS<\/h1>\n<table dir=\"ltr\">\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Product:<\/strong> Lamotrigine<\/td>\n<td colspan=\"2\"><strong>CAS No.: <\/strong>84057-84-1<\/td>\n<td><strong>Spec. No.: <\/strong>APC-QC-SPEC-382-00<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\"><strong>Issue Date: <\/strong>Apr, 2023<\/td>\n<td colspan=\"2\"><strong>Valid up to:<\/strong> Apr, 2024<\/td>\n<td><strong>Reference: <\/strong>USP44<\/td>\n<\/tr>\n<tr>\n<td><strong>Tests<\/strong><\/td>\n<td colspan=\"4\">\n<h2>Specifications<\/h2>\n<\/td>\n<\/tr>\n<tr>\n<td>Description<\/td>\n<td colspan=\"4\">A white to pale cream-colored powder.<\/td>\n<\/tr>\n<tr>\n<td>Solubility<\/td>\n<td colspan=\"4\">Slightly soluble in 0.1N hydrochloric acid, in acetone, in methanol, and in water.<\/td>\n<\/tr>\n<tr>\n<td>Identification<\/td>\n<td colspan=\"4\">A: Infrared Spectroscopy<\/p>\n<p>B: The retention time of the major peak of the sample solution corresponds to that of the standard solution, as obtained in the assay.<\/td>\n<\/tr>\n<tr>\n<td>Loss on drying<\/td>\n<td colspan=\"4\">NMT 0.5% (at 105\u00b0C for 3 h)<\/td>\n<\/tr>\n<tr>\n<td>Residue on ignition<\/td>\n<td colspan=\"4\">NMT 0.1%<\/td>\n<\/tr>\n<tr>\n<td>Residual Solvents<\/td>\n<td colspan=\"4\">Methanol: NMT 3000 ppm (Class II)<\/td>\n<\/tr>\n<tr>\n<td>Limit of Lamotrigine Related Compound B (HPLC)<\/td>\n<td colspan=\"4\">NMT 0.1 %<\/td>\n<\/tr>\n<tr>\n<td>Organic Impurities (HPLC)<\/td>\n<td colspan=\"4\">Lamotrigine related Compound C: NMT 0.1%<\/p>\n<p>Lamotrigine related Compound D: NMT 0.2%<\/p>\n<p>Any individual unspecified impurity: NMT 0.1%<\/p>\n<p>Total impurities, excluding Related Compound B: NMT 0.2%<\/td>\n<\/tr>\n<tr>\n<td>Assay (HPLC)<\/td>\n<td colspan=\"4\">98.0% to 102.0% (on the dried basis)<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\"><strong>Prepared by:<\/strong> M. Shahbazi, B.Sc.Chem.<\/td>\n<td colspan=\"2\"><strong>Checked by:<\/strong> A. Forghani, B.Sc.Chem.<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\"><strong>Approved by:<\/strong> F. Javadizadeh, M.Sc.Chem.<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\"><strong>Storage:<\/strong> Preserve in tight containers. Store at room temperature.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Description (USP 44) Drug Substance General Information (ICH 3.2.S.1) 1.1. Nomenclature (ICH 3.2.S.1.1) International non-proprietary name:\u00a0 Lamotrigine (Brand Name: Lamictl) Compendial name:\u00a0 Lamotrigine Chemical name:\u00a0 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl); 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine. Arasto\u2019s code:\u00a0 LAM CAS Registry Number: [84057-84-1]. Drug Substance General Information (ICH 3.2.S.1) 1.2. Structure (ICH 3.2.S.1.2) Empirical formula: C9H7Cl2N5 Molecular Weight: 256.09 g\/mol Drug Substance General [&hellip;]<\/p>\n","protected":false},"featured_media":7112,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_cat":[72],"product_tag":[],"class_list":["post-6133","product","type-product","status-publish","has-post-thumbnail","hentry","product_cat-72"],"_links":{"self":[{"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product\/6133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/comments?post=6133"}],"version-history":[{"count":1,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product\/6133\/revisions"}],"predecessor-version":[{"id":7114,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product\/6133\/revisions\/7114"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/media\/7112"}],"wp:attachment":[{"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/media?parent=6133"}],"wp:term":[{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product_cat?post=6133"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/arasto.com\/fa\/wp-json\/wp\/v2\/product_tag?post=6133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}